New Results
Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death
Keith Woodley, Laura S Dillingh, George Giotopoulos, Pedro Madrigal, Kevin M. Rattigan, Celine Philippe, Ryan Asby, Vilma Dembitz, Aoife S.M. Magee, Louie N van de Lagemaat, Christopher Mapperley, Sophie C James, Konstantinos Tzelepis, Kevin Rouault-Pierre, George S. Vassiliou, Kamil R Kranc, Gudmundur Helgason, Brian J.P Huntly, Paolo Gallipoli
doi: https://doi.org/10.1101/2022.05.16.492042
Keith Woodley
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Laura S Dillingh
2Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
George Giotopoulos
2Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
3Department of Haematology, University of Cambridge, Cambridge, United Kingdom
Pedro Madrigal
2Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
3Department of Haematology, University of Cambridge, Cambridge, United Kingdom
Kevin M. Rattigan
4Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
Celine Philippe
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Ryan Asby
3Department of Haematology, University of Cambridge, Cambridge, United Kingdom
Vilma Dembitz
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Aoife S.M. Magee
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Louie N van de Lagemaat
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Christopher Mapperley
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Sophie C James
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Konstantinos Tzelepis
2Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
5Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom
Kevin Rouault-Pierre
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
George S. Vassiliou
2Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
3Department of Haematology, University of Cambridge, Cambridge, United Kingdom
Kamil R Kranc
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Gudmundur Helgason
4Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
Brian J.P Huntly
2Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
3Department of Haematology, University of Cambridge, Cambridge, United Kingdom
Paolo Gallipoli
1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Posted May 16, 2022.
Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death
Keith Woodley, Laura S Dillingh, George Giotopoulos, Pedro Madrigal, Kevin M. Rattigan, Celine Philippe, Ryan Asby, Vilma Dembitz, Aoife S.M. Magee, Louie N van de Lagemaat, Christopher Mapperley, Sophie C James, Konstantinos Tzelepis, Kevin Rouault-Pierre, George S. Vassiliou, Kamil R Kranc, Gudmundur Helgason, Brian J.P Huntly, Paolo Gallipoli
bioRxiv 2022.05.16.492042; doi: https://doi.org/10.1101/2022.05.16.492042
Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death
Keith Woodley, Laura S Dillingh, George Giotopoulos, Pedro Madrigal, Kevin M. Rattigan, Celine Philippe, Ryan Asby, Vilma Dembitz, Aoife S.M. Magee, Louie N van de Lagemaat, Christopher Mapperley, Sophie C James, Konstantinos Tzelepis, Kevin Rouault-Pierre, George S. Vassiliou, Kamil R Kranc, Gudmundur Helgason, Brian J.P Huntly, Paolo Gallipoli
bioRxiv 2022.05.16.492042; doi: https://doi.org/10.1101/2022.05.16.492042
Subject Area
Subject Areas
- Biochemistry (11740)
- Bioengineering (8750)
- Bioinformatics (29189)
- Biophysics (14967)
- Cancer Biology (12093)
- Cell Biology (17410)
- Clinical Trials (138)
- Developmental Biology (9420)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18301)
- Genetics (12239)
- Genomics (16797)
- Immunology (11865)
- Microbiology (28070)
- Molecular Biology (11583)
- Neuroscience (60953)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10425)
- Synthetic Biology (2884)
- Systems Biology (7338)
- Zoology (1651)